Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4202 - Phase 1b/2a study of RX-5902, a novel Orally Bioavailable Inhibitor of Phosphorylated P68, which prevents nuclear _-catenin Translocation in patients with Triple Negative Breast Cancer

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Clinical Research

Tumour Site

Breast Cancer

Presenters

Jennifer Diamond

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

J.R. Diamond1, E. Andreopoulou2, A.M. Favret3, R. Nanda4, C. Peterson5, E. Benaim6

Author affiliations

  • 1 Medical Oncology, University of Colorado Cancer Center Anschutz Cancer Pavilion, 80045 - Aurora/US
  • 2 Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, 10065 - New York/US
  • 3 Oncology, Virginia Cancer Specialists, 22031 - Fairfax/US
  • 4 Oncology, University of Chicago, 60637 - Chicago/US
  • 5 Clinical Operations, Rexahn Pharmaceuticals, Inc, Rockville/US
  • 6 Clinical Operations, Rexahn Pharmaceuticals, 20850 - Rockville/US
More

Resources

Abstract 4202

Background

RX5902 is an oral anti-tumor and immune modulating drug targeting the phosphorylated form of p68 (also known as DDX5), a member of the DEAD box family of RNA helicases. Phosphorylated p68 may play a vital role in cell proliferation and tumor/cancer progression by affecting elements in the Wnt Canonical pathway.

Trial design

This study is conducted as a phase 1b/2a with a 2-stage design. In stage 2 of the phase 2a study, eligible subjects (aged ≥ 18 years) are those diagnosed with triple negative breast cancer, refractory intolerant or ineligible to receive approved standard therapies. There is no limit on the number of prior therapies. Subjects need to have measurable or evaluable disease per RECIST ver 1.1, ECOG performance of 0 or 1 and normal organ function. Use of potent inhibitors or inducers of CYP3A4/3A5, within 14 days of planned study treatment, are excluded. Eligible subjects, who have been fasting, will receive oral RX-5902 at 250 mg administered 5 times per week followed by 2 days off for 4 weeks in each cycle. Treatment will continue for 6 or more cycles, or until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or decision to discontinue. Primary endpoint is progression free survival (by RECIST v1.1); secondary end points include safety, overall response rate, time to progression and duration of response (by RECIST v1.1), duration of response. adverse events will be graded per NCI CTCAE v4.0. Response will be assessed every 8 weeks. Exploratory endpoints include biochemical levels of drug targets. Approximately 40 evaluable subjects will be enrolled in stage 2 of the phase 2.

Clinical trial identification

NCT02003092.

Legal entity responsible for the study

Rexahn Pharmaceuticals Inc.

Funding

Rexahn Pharmaceuticals, Inc.

Editorial Acknowledgement

Disclosure

C. Peterson, E. Benaim: Employee: Rexahn Pharmaceuticals. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.